Sensus Healthcare (NASDAQ:SRTS) Price Target Raised to $11.00 at HC Wainwright

Sensus Healthcare (NASDAQ:SRTS) had its target price hoisted by HC Wainwright from $10.00 to $11.00 in a research note released on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Maxim Group upped their price target on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a report on Friday.

Sensus Healthcare Trading Up 10.1 %

SRTS stock opened at $8.41 on Monday. The stock’s 50 day simple moving average is $6.37 and its 200 day simple moving average is $5.97. Sensus Healthcare has a 12-month low of $2.02 and a 12-month high of $8.69. The stock has a market capitalization of $137.83 million, a PE ratio of 14.60 and a beta of 1.04.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its holdings in Sensus Healthcare by 34.4% in the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock worth $2,087,000 after purchasing an additional 100,294 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Sensus Healthcare by 128.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after buying an additional 93,511 shares during the period. Marshall Wace LLP boosted its stake in shares of Sensus Healthcare by 152.4% in the 2nd quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after buying an additional 46,732 shares during the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of Sensus Healthcare in the first quarter worth $155,000. Finally, Acadian Asset Management LLC increased its position in Sensus Healthcare by 578.6% during the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock valued at $239,000 after acquiring an additional 38,474 shares during the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.